

# CITATION REPORT

List of articles citing

**Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial**

**DOI: 10.1001/jamaophthalmol.2017.4030**  
**JAMA Ophthalmology, 2017, 135, 1206-1213.**

**Source:** <https://exaly.com/paper-pdf/67396431/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
217	Ophthalmic Application of Anti-VEGF Therapy. <b>2017</b> , 6, 479-480		3
216	Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. <b>2018</b> , 125, 708-724		187
215	A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. <b>2018</b> , 62, 137-143		2
214	Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , <b>2018</b> , 136, 786-793	3.9	121
213	Comparing Aflibercept Monotherapy With Aflibercept Plus Rescue Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: PLANET or Asteroid?. <i>JAMA Ophthalmology</i> , <b>2018</b> , 136, 794-795	3.9	2
212	Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports. <b>2018</b> , 18, 284		3
211	Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. <b>2018</b> , 2018, 1425707		10
210	The needle, or the knife?. <b>2018</b> , 46, 851-853		
209	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences. <b>2018</b> , 12, 2177-2181		4
208	Age-related macular degeneration. <b>2018</b> , 392, 1147-1159		455
207	Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. <b>2018</b> , 12, 1789-1799		11
206	Microperimetry and multimodal imaging in polypoidal choroidal vasculopathy. <b>2018</b> , 8, 15769		2
205	Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intravitreal aflibercept (Eylea), a case report. <b>2018</b> , 18, 267		4
204	The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. <b>2018</b> , 19,		15
203	Sudden-Onset Unilateral Macular Hemorrhage in a Middle-aged Man. <i>JAMA Ophthalmology</i> , <b>2018</b> , 136, 1301-1302	3.9	
202	Optical Coherence Tomography: Retinal Imaging. <b>2018</b> , 19-36		
201	Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population. <b>2018</b> , 240, 208-212		6

200	Choroidal remodeling after photodynamic therapy for polypoidal choroidal vasculopathy. <b>2018</b> , 50, 978-979	
199	Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen. <b>2018</b> , 18, 144	5
198	Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy. <b>2018</b> , 32, 1731-1739	4
197	Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. <b>2019</b> , 103, 617-622	12
196	Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. <b>2019</b> , 103, 844-848	13
195	A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. <b>2019</b> , 3, 16-26	22
194	Pachychoroid disease. <b>2019</b> , 33, 14-33	247
193	Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. <b>2019</b> , 9, 11389	12
192	Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy. <b>2019</b> , 3, 744-752	27
191	Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. <b>2019</b> , 63, 389-395	3
190	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. <b>2019</b> , 73, 100770	122
189	Incrementally does it: Multicolour imaging in polypoidal choroidal vasculopathy. <b>2019</b> , 47, 569-570	
188	Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy. <b>2019</b> , 19, 153	4
187	Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy. <b>2019</b> , 63, 382-388	5
186	Efficacy of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy Associated with and without Pachychoroid Phenotypes. <b>2019</b> , 3, 1016-1025	11
185	Polypoidal Choroidal Vasculopathy. <b>2019</b> , 7, 66-72	2
184	Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. <b>2019</b> , 257, 1411-1418	10
183	Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. <b>2019</b> , 27, 227-233	3

182	Enlargement of polypoidal choroidal vasculopathy lesion without exudative findings assessed in en face optical coherence tomography images. <b>2019</b> , 257, 1621-1629		0
181	RETINA. <b>2019</b> , 39, 1-12		
180	Insights of Swept-Source Optical Coherence Tomographic Angiography on the Structures in Polypoidal Choroidal Vasculopathy. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 650-651	3.9	1
179	Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. <b>2019</b> , 60, 1088-1095		19
178	Polypoidal choroidal vasculopathy: a comprehensive clinical update. <b>2019</b> , 11, 2515841419831152		14
177	Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. <b>2019</b> , 204, 80-89		47
176	Diagnosing Polypoidal Choroidal Vasculopathy Without Indocyanine Green Angiography. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 667-668	3.9	1
175	Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 661-667	3.9	21
174	Different imaging characteristics between unilateral and bilateral polypoidal choroidal vasculopathy. <b>2019</b> , 26, 1-7		1
173	Multicolor Fundus Imaging of Polypoidal Choroidal Vasculopathy. <b>2019</b> , 3, 400-409		6
172	Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps. <b>2019</b> , 9, 1487		2
171	Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy. <b>2019</b> , 2019, 1609717		5
170	Approche diagnostique et thérapeutique de la vasculopathie polypoïdale choroïdienne. Recommandations de la Fédération France Macula. <b>2019</b> , 42, 762-777		
169	Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. <b>2019</b> , 41, 813-845		29
168	Asia-Pacific Technology and Trend Survey 2016-2017. <b>2019</b> , 8, 43-54		3
167	New Concepts in Polypoidal Choroidal Vasculopathy Imaging: A Focus on Optical Coherence Tomography and Optical Coherence Tomography Angiography. <b>2019</b> , 8,		2
166	Multicolour imaging for the detection of polypoidal choroidal vasculopathy and age-related macular degeneration. <b>2019</b> , 47, 621-630		4
165	A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy: Fight Retinal Blindness! Cohort. <b>2019</b> , 3, 220-229		9

164	The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. <b>2019</b> , 63, 100-108		7
163	EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy. <b>2019</b> , 47, 614-620		11
162	Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan. <b>2020</b> , 119, 569-576		6
161	Angiographic features of polypoidal choroidal vasculopathy using indocyanine green angiography and optical coherence tomography angiography: A comparative study. <b>2020</b> , 30, 1076-1081		1
160	POSTTREATMENT POLYP REGRESSION AND RISK OF MASSIVE SUBMACULAR HEMORRHAGE IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. <b>2020</b> , 40, 468-476		15
159	Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy. <b>2020</b> , 30, 1473-1479		2
158	Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy. <i>JAMA Ophthalmology</i> , <b>2020</b> , 138, 251-259	3.9	5
157	Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Anti-Vascular Endothelial Growth Factor Treatment Response in Caucasians. <b>2020</b> , 243, 178-186		7
156	Polypoidal choroidal vasculopathy in Canada. <b>2020</b> , 55, 199-211		1
155	COMPARISON OF MULTICOLOR IMAGING AND COLOR FUNDUS PHOTOGRAPHY IN THE DETECTION OF PATHOLOGICAL FINDINGS IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. <b>2020</b> , 40, 1512-1519		2
154	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. <b>2020</b> , 4, 403-414		12
153	REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study. <b>2020</b> , 40, 1529-1539		4
152	T and genetic variations between Asian and Caucasian polypoidal choroidal vasculopathy. <b>2021</b> , 105, 1716-1723		2
151	Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis. <b>2020</b> , 29,		9
150	Pachychoroid spectrum disease. <b>2021</b> , 99, e806-e822		14
149	Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study. <b>2020</b> , 20, 324		0
148	Recent theranostic paradigms for the management of Age-related macular degeneration. <b>2020</b> , 153, 105489		5
147	One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. <b>2020</b> , 9, 1069-1082		4

146	Photodynamic therapy induces autophagy-mediated cell death in human colorectal cancer cells via activation of the ROS/JNK signaling pathway. <b>2020</b> , 11, 938	14
145	The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. <b>2020</b> , 2020, 4924053	1
144	Insights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs. <b>2020</b> , 17, 4018-4028	3
143	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , <b>2020</b> , 138, 935-942	38
142	Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. <b>2020</b> , 15, e0237330	5
141	Macular Disorders. <b>2020</b> ,	
140	Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. <b>2020</b> , 10, 8337	5
139	Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment. <b>2020</b> , 9, 260-268	5
138	Decreased Periodicity of Reactivation Interval in Neovascular Age-Related Macular Degeneration in Patients with a Late First Reactivation After Initial Treatment. <b>2020</b> , 36, 703-710	1
137	Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. <b>2020</b> , 64, 265-270	2
136	Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy with Anti-VEGF Therapy. <b>2020</b> , 4, 433-436	1
135	Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy. <b>2020</b> , 15, e0235213	4
134	Early changes of vascular lesions and responses to combined photodynamic therapy in patients with polypoidal choroidal vasculopathy. <b>2020</b> , 40, 1335-1345	2
133	One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovascularopathy without polypoidal lesions. <b>2020</b> , 64, 203-209	16
132	Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. <b>2020</b> , 15, e0229231	8
131	Tumor-targeted upconverting nanoplatform constructed by host-guest interaction for near-infrared-light-actuated synergistic photodynamic-/chemotherapy. <b>2020</b> , 390, 124516	18
130	Photodynamic therapy with smart nanomedicine. <b>2020</b> , 43, 22-31	32
129	Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV. <b>2020</b> , 2020, 2428348	1

128	One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovascularopathy. <b>2020</b> , 258, 1279-1285	12
127	Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. <b>2020</b> , 9, 329-342	8
126	Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy. <b>2020</b> , 20, 150	2
125	Prevalence of polypoidal choroidal vasculopathy in Caucasian patients as estimated from optical coherence tomography signs. <b>2021</b> , 35, 1011-1012	1
124	One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy. <b>2021</b> , 259, 1455-1462	2
123	Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. <b>2021</b> , 128, 443-452	22
122	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. <b>2021</b> , 82, 100906	27
121	Pachychoroid: current concepts on clinical features and pathogenesis. <b>2021</b> , 259, 1385-1400	17
120	The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. <b>2021</b> , 259, 855-872	1
119	Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices. <b>2021</b> , 41, 753-765	2
118	The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy. <b>2021</b> , 14,	0
117	Pharmacotherapy of Age-Related Macular Degeneration. <b>2021</b> , 1-26	
116	Choroidal congestion mouse model: Could it serve as a pachychoroid model?. <b>2021</b> , 16, e0246115	7
115	Vitreoretinal Society of India practice pattern survey 2020: Medical retina. <b>2021</b> , 69, 1430-1439	2
114	Retina. <b>2021</b> , 89-114	
113	Comparative analysis of polypoidal choroidal vasculopathy with and without hemorrhage treated by anti-VEGF monotherapy. <b>2021</b> , 259, 1741-1750	0
112	One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity. <b>2021</b> , 35, 26-36	
111	Systematic review with network meta-analysis of anti-vascular endothelial growth factor use in managing polypoidal choroidal vasculopathy. <b>2021</b> , 11, 2735	1

110	Comparison of Polypoidal Choroidal Vasculopathy Lesion Sizes Measured on Multicolor Imaging and Indocyanine Green Angiography. <b>2021</b> , 10, 35	0
109	One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient. <b>2021</b> , 21, 94	
108	One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovascularopathy. <b>2021</b> , 35, 3367-3375	5
107	Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. <b>2021</b> ,	5
106	Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration. <b>2021</b> , 21, 98	1
105	Two-year results of a treat and extend regimen with aflibercept in Caucasian patients with aneurysmal type 1 neovascularization. <b>2021</b> , 11206721211001313	2
104	Short-term outcomes of intravitreal brolocizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. <b>2021</b> , 11, 6759	14
103	Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovascularopathy. <b>2021</b> , 16, e0248760	1
102	Timing of Complete Polypoidal Regression after Intravitreal Aflibercept Treatments in Polypoidal Choroidal Vasculopathy. <b>2021</b> , 6, 21-21	2
101	Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study. <b>2021</b> , 18,	0
100	Pachydrusen, choroidal vascular hyperpermeability, and punctate hyperfluorescent spots. <b>2021</b> , 259, 2391-2400	0
99	One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy. <b>2021</b> , 31, 2868-2875	1
98	Baseline Optical Coherence Tomography Parameters That May Influence 6 Months Treatment Outcome of Polypoidal Choroidal Vasculopathy Eyes with Combination Therapy: A Short-Term Pilot Study. <b>2021</b> , 18,	
97	POLYPOIDAL CHOROIDAL VASCULOPATHY FEATURES VARY ACCORDING TO SUBFOVEAL CHOROIDAL THICKNESS. <b>2021</b> , 41, 1084-1093	4
96	Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography. <b>2021</b> , 11,	1
95	Replacement of polyps with type 1 macular neovascularization in polypoidal choroidal vasculopathy imaged with swept source OCT angiography. <b>2021</b> , 22, 101057	1
94	Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry. <b>2021</b> , 49, 652-663	3
93	The Past and Present of Photodynamic Therapy in Ophthalmology. <b>2021</b> , 42, 78-88	



92	Myopic foveal detachment associated with pachychoroid characteristics. <b>2021</b> , 21, 288	
91	Evolving treatment paradigms for PCV. <b>2021</b> ,	1
90	Pachychoroid neovascularopathy: A comparative review on pathology, clinical features, and therapy. <b>2021</b> , 11206721211036290	
89	Efficacy and safety of Intravitreal Aflibercept Vs Verteporfin Photodynamic Therapy in a Caucasian Population with Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. <b>2021</b> ,	0
88	Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy. <b>2021</b> , 11, e050252	0
87	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <b>2021</b> , 11, 14623	0
86	Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration. <b>2021</b> , 1	0
85	Age-Related Macular Degeneration. <b>2021</b> , 385, 539-547	12
84	Long-term outcomes of focal laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. <b>2021</b> , 14, 1402-1407	0
83	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. <b>2021</b> , 65, 741-760	2
82	The role of oral steroids in the treatment of photodynamic therapy-associated exudative maculopathy, a case report and review of the literature. <b>2021</b> , 35, 102390	2
81	Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolucizumab-Related Intraocular Inflammation. <b>2021</b> , 12, 797-803	1
80	Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan. <b>2021</b> , 5, 954-961	2
79	Current Understanding of Polypoidal Choroidal Vasculopathy. <b>2021</b> , 61-71	
78	Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy. <b>2021</b> , 11, 1194	0
77	Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study. <b>2021</b> , 11, 470	3
76	Current Management of Age-Related Macular Degeneration. <b>2021</b> , 1256, 295-314	1
75	Non-Oncologic Applications of Nanomedicine-Based Phototherapy. <b>2021</b> , 9,	13

74	Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study. <b>2021</b> , 65, 344-353	1
73	Vortex Vein Anastomosis at the Watershed in Pachychoroid Spectrum Diseases. <b>2020</b> , 4, 938-945	24
72	RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: Predictors of Visual and Anatomical Response in the EVEREST II Study. <b>2021</b> , 41, 387-392	2
71	Long-term results of rescue photodynamic therapy for type 1 neovascularization refractory to anti-vascular endothelial growth factor. <b>2021</b> , 99, e899-e907	3
70	Flow signal change in polyps after anti-vascular endothelial growth factor therapy. <b>2020</b> , 15, e0241230	1
69	[Specific biomarkers of response to antiangiogenic therapy]. <b>2020</b> , 136, 117-124	3
68	One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study. <b>2018</b> , 11, 1802-1808	9
67	New Paradigms in Polypoidal Choroidal Vasculopathy Management: The Impact of Recent Multicenter, Randomized Clinical Trials. <b>2018</b> , 49, 4-10	7
66	Polypoidal choroidal vasculopathy: Pearls in diagnosis and management. <b>2018</b> , 66, 896-908	15
65	Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naïve polypoidal choroidal vasculopathy. <b>2019</b> , 67, 1114-1118	4
64	Current management strategy of polypoidal choroidal vasculopathy. <b>2018</b> , 66, 1727-1735	7
63	Polypoidal choroidal vasculopathy: An update on current management and review of literature. <b>2019</b> , 9, 72-92	15
62	Pachychoroid disease and its association with retinal vein occlusion: a case-control study. <b>2021</b> , 11, 19854	0
61	The Contemporary Role of Photodynamic Therapy in the Treatment of Pachychoroid Diseases. <b>2021</b> , 2021, 6590230	
60	Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy. <b>2021</b> , 11, 20115	0
59	Efficacy of combined anti-VEGF and photodynamic therapy for bilateral diffuse uveal melanocytic proliferation: Case series. <b>2021</b> , 100, e27578	1
58	Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy. <b>2019</b> , 67, 1119-1120	
57	Verteporfin Photodynamic Therapy for the Treatment of Choroidal Conditions—An Overview. <b>2019</b> , 12, 69	

56	[Current understanding of pachychoroid spectrum diseases]. <b>2019</b> , 135, 293-298	0
55	Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies. <b>2019</b> , 16, 151-158	2
54	Modern aspects of polypoidal choroidal vasculopathy diagnosis and treatment. <b>2019</b> , 12, 93-100	
53	Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD. <b>2020</b> , 1-53	
52	REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. <b>2021</b> , 41, 156-161	0
51	Genomics in Choroidal Neovascularization. <b>2020</b> , 57-69	
50	Management Strategies for Neovascular AMD. <b>2020</b> , 99-108	
49	Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. <b>2021</b> , 99, e336-e345	1
48	Polypoidal Choroidal Vasculopathy. <b>2020</b> , 29-37	
47	Patient Investigations and Interpretation. <b>2020</b> , 5-62	
46	Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. <b>2021</b> , 11, 21572	0
45	Cost and Outcomes Analysis of Polypoidal Choroidal Vasculopathy (Aneurysmal Type 1 Neovascularization) Treatment Strategies. <b>2021</b> , 5, 227-231	1
44	Porphyrin/Chlorin Derivatives as Promising Molecules for Therapy of Colorectal Cancer. <b>2021</b> , 26,	5
43	Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand. <b>2021</b> , 13, 917-926	0
42	One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study. <b>2021</b> , 1	
41	Evolution of polypoidal lesions following treatment of Polypoidal Choroidal Vasculopathy. <b>2021</b> , 100082	1
40	Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy. <b>2021</b> ,	1
39	Infographic: Everest II study "Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment".. <b>2022</b> ,	0

- 38 Observation of Photodynamic Therapy Combined with Intravitreal Injection of Ranibizumab versus Mono Therapy of Intravitreal Injection of Ranibizumab for Central Serous Chorioretinopathy Switched to Type 1 Choroidal Neovascularization. **2021**, 10, 198-207
- 37 Publication Trends of Research on Polypoidal Choroidal Vasculopathy During 2001-2020: A 20-Year Bibliometric Study.. **2021**, 8, 785126 ○
- 36 Treatment of macular diseases: an overview of key randomized clinical trials. **2022**, 14, 137-148 ○
- 35 Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept.. **2022**, 42, 601
- 34 One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovascularopathy refractory to anti-vascular endothelial growth factor therapy.. **2022**, 260, 2029
- 33 Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases.. **2022**, 14, 402-415 1
- 32 Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy.. **2022**, 1 ○
- 31 Diagnosis of Polypoidal Choroidal Vasculopathy From Fluorescein Angiography Using Deep Learning.. **2022**, 11, 6 ○
- 30 One year outcomes of eyes with polypoidal choroidal vasculopathy with  $\geq$ 0/40 visual acuity treated with anti-vascular endothelial growth factor agents.. **2021**, 35, 84-87
- 29 Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy - short term study.. **2021**, 35, 88-92
- 28 [Current view on the issue of insufficient effectiveness of anti-VEGF therapy for age-related macular degeneration].. **2022**, 138, 90-99 1
- 27 Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.. **2022**, ○
- 26 Association of flow signals within polyps on optical coherence tomography angiography with treatment responses after combination therapy for polypoidal choroidal vasculopathy.. **2021**,
- 25 One-Year Outcome of Combination Therapy with Full or Reduced Photodynamic Therapy and One Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovascularopathy.. **2022**, 15,
- 24 Pharmacotherapy of Age-Related Macular Degeneration. **2022**, 3619-3644
- 23 Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD. **2022**, 3565-3617
- 22 One-year outcomes of intravitreal brolocizumab injections in patients with polypoidal choroidal vasculopathy.. **2022**, 12, 7987 ○
- 21 One-year results of treat-and-extend regimen with intravitreal brolocizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.. **2022**, 12, 8195 ○

- 20 Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases. **2022**, 12,
- 19 A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration. 9, ○
- 18 Brolucizumab in polypoidal choroidal vasculopathy.
- 17 Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey. **2022**, 17, e0271447 ○
- 16 Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy. **2022**, 22,
- 15 Polypoidal Choroidal Vasculopathy Based on Non-ICGA Criteria In White Patients With Neovascular Age-Related Macular Degeneration. **2022**,
- 14 Occlusion of a Vortex Vein After Treatment With Half-Fluence Photodynamic Therapy Combined With Intravitreal Aflibercept Injection for Pachychoroid Neovascularopathy. **2022**,
- 13 Predictors and importance of complete polypoidal lesion regression in the EVEREST II study. **2022**, Publish Ahead of Print,
- 12 Current Trends in Clinical Characteristics, Diagnosis, and Treatment of Polypoidal Choroidal Vasculopathy: A Perspective from Vietnam. **2022**, 11, 4678 ○
- 11 Nanotechnology interventions in neuroscience: current perspectives and strategies. **2022**, 255-289 ○
- 10 Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission. **2022**, 12, 1
- 9 Photodynamic Therapy-Induced Acute Exudative Maculopathy (PAEM): Prevalence, Impact and Management Strategies. Volume 16, 3145-3154 ○
- 8 Optical Coherence Tomography Features for Identifying Posttreatment Complete Polypoidal Regression in Polypoidal Choroidal Vasculopathy. **2022**, 11, 408-416 ○
- 7 Spin-Coating-Based Facile Annular Photodynamic Intraocular Lens Fabrication for Efficient and Safer Posterior Capsular Opacification Prevention. **2022**, 14, 48341-48355 1
- 6 Two-year clinical outcomes of triple therapy with photodynamic therapy, anti-vascular endothelial growth factor agent, and triamcinolone acetonide for neovascular age-related macular degeneration. ○
- 5 Polypoidal choroidal vasculopathy characteristics and response to treatment with bevacizumab in caucasian patients. **2022**, 8, ○
- 4 Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment. Volume 17, 53-70 ○
- 3 Updates on Risk Factors, Diagnosis, and Treatments of Polypoidal Choroidal Vasculopathy. Publish Ahead of Print, ○

- 2 Joint Multimodal Deep Learning-based Automatic Segmentation of Indocyanine Green Angiography and OCT Images for Assessment of Polypoidal Choroidal Vasculopathy Biomarkers. **2023**, 3, 100292 ○
- 1 Photodynamic and Anti-VEGF Therapy for Polypoidal Choroidal Vasculopathy - Real World Outcomes in a Caucasian Population. **2023**, 17, ○